RPL17 and neoplasm: The observed survival benefit is likely driven by the synergistic activation of T-cells via dual blockade of the PD-1/PD-L1 and CTLA-4 pathways, potentially enhancing T-cell priming, infiltration, and tumor microenvironment modulation (56).